395 related articles for article (PubMed ID: 25165542)
1. The host immune response to Clostridium difficile infection.
Solomon K
Ther Adv Infect Dis; 2013 Feb; 1(1):19-35. PubMed ID: 25165542
[TBL] [Abstract][Full Text] [Related]
2. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.
Sun X; Hirota SA
Mol Immunol; 2015 Feb; 63(2):193-202. PubMed ID: 25242213
[TBL] [Abstract][Full Text] [Related]
3. The host immune response to Clostridium difficile.
Kelly CP; Kyne L
J Med Microbiol; 2011 Aug; 60(Pt 8):1070-1079. PubMed ID: 21415200
[TBL] [Abstract][Full Text] [Related]
4. Host recognition of Clostridium difficile and the innate immune response.
Cowardin CA; Petri WA
Anaerobe; 2014 Dec; 30():205-9. PubMed ID: 25223264
[TBL] [Abstract][Full Text] [Related]
5. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate
Maseda D; Zackular JP; Trindade B; Kirk L; Roxas JL; Rogers LM; Washington MK; Du L; Koyama T; Viswanathan VK; Vedantam G; Schloss PD; Crofford LJ; Skaar EP; Aronoff DM
mBio; 2019 Jan; 10(1):. PubMed ID: 30622186
[No Abstract] [Full Text] [Related]
7. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile and the disease it causes.
Norén T
Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
[TBL] [Abstract][Full Text] [Related]
9.
Schäffler H; Breitrück A
Front Microbiol; 2018; 9():646. PubMed ID: 29692762
[No Abstract] [Full Text] [Related]
10. Immune-based treatment and prevention of Clostridium difficile infection.
Zhao S; Ghose-Paul C; Zhang K; Tzipori S; Sun X
Hum Vaccin Immunother; 2014; 10(12):3522-30. PubMed ID: 25668664
[TBL] [Abstract][Full Text] [Related]
11. Host response to Clostridium difficile infection: Diagnostics and detection.
Usacheva EA; Jin JP; Peterson LR
J Glob Antimicrob Resist; 2016 Dec; 7():93-101. PubMed ID: 27693863
[TBL] [Abstract][Full Text] [Related]
12. Immune responses induced by Clostridium difficile.
Péchiné S; Collignon A
Anaerobe; 2016 Oct; 41():68-78. PubMed ID: 27108093
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.
Jose S; Madan R
Anaerobe; 2016 Oct; 41():85-90. PubMed ID: 27063896
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.
Gerding DN
Discov Med; 2012 Jan; 13(68):75-83. PubMed ID: 22284786
[TBL] [Abstract][Full Text] [Related]
15. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
Kelly CP; Chen X; Williams D; Xu H; Cuddemi CA; Daugherty K; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
Clin Infect Dis; 2020 Mar; 70(6):1083-1093. PubMed ID: 31211839
[TBL] [Abstract][Full Text] [Related]
16. Current advances related to Clostridium difficile infection.
Kim YG; Jang BI
Indian J Med Res; 2015 Feb; 141(2):172-4. PubMed ID: 25900952
[TBL] [Abstract][Full Text] [Related]
17. Protection from Clostridium difficile infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice.
Johnston PF; Gerding DN; Knight KL
Infect Immun; 2014 Feb; 82(2):522-31. PubMed ID: 24478068
[TBL] [Abstract][Full Text] [Related]
18. Immune response to Clostridium difficile infection.
Kelly CP
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1048-53. PubMed ID: 8944364
[TBL] [Abstract][Full Text] [Related]
19. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
20. Breakthroughs in the treatment and prevention of Clostridium difficile infection.
Kociolek LK; Gerding DN
Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):150-60. PubMed ID: 26860266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
